PROCESS FOR PREPARING IMIDAZOLE COMPOUNDS

Abstract: There are prepared compounds of the formulae where R is a lower alkyl, chlorine, or bromine and n is an integer from 1 to 5. The compounds of formula (1) can be used to make erythro-9-(2-hydroxy-3-nonyl) hypoxanthine and its homologues and also to make the compounds of formulae (2) and (3). All three classes of compounds are useful as immunomodulators.

Description: IMIDAZOLE COMPOUNDS BACKGROUND OF THE INVENTION Simon U.S. patents 4,221,909 and 4,211,794 and Giner-Sorolla U.S. patent 4,221,910 and Faanes International Journal of Immunopharinacology, Vol. 2, No. 3, page 197 (1980), Florentine, International Journal of Immunpharmacology, Vol. 2, No. 3, page 240 (1980), Hadden, International Journal of Immunopharmacology, Vol. 2, No. 3, page 198 (1980), Pahwa, International Journal of Immunopharmacology, Vol. 2, No. 3, page 199 (1980), Wybran, International Journal of Immunopharmacology, Vol. 2, No. 3, page 201 (1980) and Simon, 4th International Congress of Immunology, Paris (1980) show that erythro--9-(2- hycroxy-3-nonyl)-hxpoxanthine (NPT 15392), as well as other re. bers of the series described in the patents cited above are potent immunomodulating agents which have been demonstrated to enhance depressed irrnunity in both animals possessing tumors, Sato, International Journal of Immunopharmacology, Vol, 2, No. 3, page 200 (1980), as well as in humans with various tumors, Simon, American Chemical Society Book of Abstracts, 182nd American Chemical Society Meeting (1981). While the synthesis of these therapeutically useful agents can be carried out by the methods described in the patents cited above, their production, esg. the production of NPT 15392, on a large scale using those methods was cumbersome, costly, and time consuming. SUMMARY OF THE INVENTION There are prepared compounds of the formulae EMI2.1 where R is lower alkyl, e.g. of 1 to 4 carbon atoms such as methyl, ethyl, propyl, or butyl or halogen of atomic weight 35 to 80, i.e. chlorine or bromine. The compound erythro-3-(2-hydroxy-3nonyl)-4-amino-imidazole-5-carboxamide (NPT 15459) is useful in producing NPT 15392 and its homologues of formula (1) above are useful in making the corresponding homologues of NPT 15392. In addition to being useful in making NPT 15392 and its homologues, NPT 15459 and its homologues are useful in preparing novel analogues of NPT 15392 (and its homologues which contain various functional groups in the 2-position of the purine ring, e.g. the compounds of formulae (2) and (3). Such derivatives would be difficult to prepare without the aid of NPT 15359 and its homologues. The compounds of formulae (1), (2), and (3) also have immunomodulating or inumunopotentiating activity. An immunopotentiator or immunomodulator is any agent which either restores depressed immune function, or enhances normal immune function, or both. Immune function is defined as the development and expression of humoral (antibody-mediated) immunity, cellular (thymocyte-mediated) immunity, or macrophage and ganulocyte mediated resistance. It logically includes agents acting directly on the cells involved i:- the expression of immune response, or on cellular o molecular mechanisms which, in turn, act to modify the function of cells involved in immune response. Augmentation of immune function may result from the action of an agent to abrogate suppressive mechanisms derived by negative-feedback influences endogenous or exogenous to the itnune system. Thus, immune potentiators have diverse mechanisms of action. Despite the diversi ty of cell site of action and biochemical mechanism of action of immunopotentiators, their applications are essentially the same; that is, to enhance host resistance. Applications of Immunopotentiators 1) The principal protective function of the immune system relates to resistance to invasion by pathogens, including viruses, rickettsia, mycoplasma, bacteria, fungi, and parasites of all types. Thus, improvement of immune response, particularly when depressed, would calculatedly improve resistance in infection or infestation by any of the above pathogens. An immunopotentiator alone or in combination with anti-infective therapy can be aprtied to any and all infectious diseases. 2) A second protective function of the immune system is thought to be resistance to engraftment of foreign tissue, either natural as in the fetal-maternal relationship; or unnatural-as performed by the transplant physician. In=nunopo- tentiators can also be used to facilitate rejection of fetal or placental tissues or to modify or induce tolerance to grafts. 3) A third protective function of the immune system is thought to be resistance to malignant cell development as in cancer. The use of immunopotentiators can be used in cancer treatment to enhance tumor rejection and to inhibit tumor recurrences followling other forms of therapy. 4) A fourth protective function involves the capacity to recognize foreignness and to maintain nonreactivity to self by positive suppressor mechanisms. In auto-immune and related disorders, immune reactivity directed at self antigens or exaggerated, elevated responses are apparent which are self-destructive. Immunopotentiators can be used to restore normal suppressor mechanisms, induce tolerance, or otherwise promote a nonr,al immune response. Each of the protective functions of the immune system can be modified by non-specific therapy with immunopotentiators alone or in combi- nation with other agents employed to improve resistance or to kill the invading pathogen. In addition, specific resistance can be augmented by use of immunopotentiators in conjunction with soe form of antigen as in a vaccine employing, for example, virus, tumor cells, etc. This use can be to induce either specific immunity or tolerance. The latter might be exe.plitied by use with antigen in allergy or auto-inunune diseases. Use of immuno- potentiators may be either therapeutic or propyl lactic; the latter particularly in aging, where infection, auto-immunity, and cancer are more common. The timing of administration and routes are variable and may be critical in determining whether a positive or negative response results. Any agent capable of augmenting immune response may inhibit it depending on timing and dose; thus, under certain circumstances an immunopotentiator could be used as an immunosuppressive agent for use in allergy, auto-immunity and transplantation. Various procedures for determining immunomodulating activity are shown in Simon E.P.O. published application 0036077, Illustrative of compounds within the invention in addition to NPT 15459 are: erythro-3- (2-hydroxy-3-amyl) -4 -amino- imidazole-5-carboxamide, erythro-3-(2-hydroxy-3-hexyl)-4-aminoimidazole- 5-carboxamide, erythro-3-(2-hydroxy-3-heptyl)-4-aminoimidazole- 5-carbozamide, erythro-3-(2-hydroxy-3-octyl)-4-amino imidazole- 5-carboxamide, erythro-9-(2-hydroxy-3-nonyl)-2-aminohypoxanthine, erythro-9-(2-hydrox-3-arnyl)-2-,nino- hypoxanthine, erythro-9-(2-hydroxy-3-hexyl)-2-aminohypoxanthine, erythro-9-(2-hydroxy-3-heptyl)-2-aminohypoxanthine, erythro-9-(2-hydroxy-3-octyl)-2-aminohypoxanthine, erythro- 9- (2-hydroxy- 3-nonyl) -2-chloro- hypoxanthine, erythro- 9- (2-hydroxy- 3-amyl) -2-chloro- hypoxanthine, erythro-9- (2-hydroxy- 3-hexyl) -2-chioro- hypoxanthine, erythro-9-(2-hydroxy-3-heptyl)-2-chlorohypoxanthine, erythro-9-(2-hydroxy-3-octyl)-2-chlorohypoxanthine, erythro-9-(2-hydroxy-3-nonyl)-2-bromohypoxanthine, erythro-9-(2-hydroxy-3-amyl)-2-bromohypoxanthine, erythro-9- (2-hydroxy-3-nonyl) -2-methyl- hypoxanthine, erythro-9-(2-hydroxy-3-amyl)-2-methylhypoxanthine, erythro-9-(2-hydroxy-3-hexyl)-2-methylhypoxanthine, erythro-9-(2-hydroxy-3-heptyl)-2-methylhypoxanthine, erythro-9-(2-hydroxy-3-octyl)-2-methylhypoxanthine, erythro-9- (2-hydroxy-3-nonyl) -2-ethyl- hypoxanthine, erythro-9-(2-hydorxy-3-hexyl)-2-ethyl- hypoxanthine, and erythro-9-(2-hydroxy-3-amyl)-2-ethyl hypoxanthine. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is the IR-spectrum of NPT 15459, and Figure 2 is the UV-spectrum of NPT 15459 DETAILED DESCRIPTION The synthesis of NPT 15459 is carried out according to the scheme presented below: EMI8.1 The other compounds within formula (1) can be prepared in the same manner by replacing erythro-3-amino-2-nonanol by the corresponding aminoalcohol, e.g. erythro-3-amino-2-pentanol and erythro-3-amino-2-octanol. In place of ethyl orthoformate there can be used other lower alkyl orthoformates, e.g. methyl orthoformate, propyl orthoformate and butyl orthoformate. Example 1 Synthesis of Erythro-3-(2-hydroxy-3-nonyl)-4amino-imidazole-5-carboxamide (NPT 95459 (V)) For improved yield, reactions (1) and (2) above are carried out sequentially without isolation of the intermediate product III. 2-amino-2-cyano- acetamide (1) (171 g, 1.71 moles) is suspended in 2200 ml of acetonitrile. Orthoformic acid triethyl- ester (II) (334 ml - 2.0 moles) and 2 ml of pyridine are added to the suspension with stirring. The suspension is heated to reflux temperature, using an oil bath preheated to 100 C. The suspension is held at boiling temperature for 40 to 60 minutes. III is produced in situ. 272.5 g of erythro-3amino-2-nonanol (1V) (1.71 moles) are then added over a 3 to 5 minute period and boiling is continued for an additional 10 to 15 minutes. The reaction is quickly chilled to room temperature. The erbthro- 3-(2-droy-3-nonyl)-4-amino-imidazole- (NPT 15459) (V) crystallizes. It is filtered by suction, washed with a small amount of acetonitrile and dried in vacuo at 70 C. Yield: 330.4 g, 72E of theory Melting point (after recrystallization from acetonitrile) : 154-158 C. SUMMARY OF CHEMICAL PROPERTIES OF (NPT 15459) Chemical or Physical Property Value M.P. 154-158 C C Theory: 58.18 Found: 57.80 N Theory: 20.87 Found: 21.00 Solubility - soluble-isopropanol - very soluble - HCl (Aq), acetic acid, methanol, ethanol - insoluble - benzene, water TLC silica gel [ethylacetate/methanol: 8:2) Rf = 0.61 Mol. Wt. 268.35 Appearance Colorless and odorless powder Identity 1. IR-spectrum: (Fig. 1) - bands at 3450 cm-Ú (-NH2) 3400-3100 cm-Ú (several) (-CONH2 a.o.) 2950 cm-Ú (-CH3-, -CH2-) 1660 cm-Ú (-imidazole) 2. UV-spectrum: (Fig. 2) - maximum at 267 nm minimum at 217 nm Found Nominal Value: Sulphate Ash not ponderable # 0,5 @ Heavy Metals < 50 ppm # 50 ppm Found Loss of Drying not ponderable # 2 @ Purity (TLC) no side spots no side spo Percentage of Side Products < 0, 2 mole % < 10 mole e Content 98, 7 X 95 - 105 % UTILIZATION OF NPT 15459 TO PRODUCE NPT 15392 The reaction scheme described below illustrates the use of @@@@@@@@@@@@@@@@@@@@@@@@@@ Reaction Scheme: : EMI11.1 C13H24N4O2 C14H22H4O2 268.35 278.35 The homologues of NPT 15392 can be prepared in the same manner from the corresponding homologues of NPT 15459. In place of ethyl ortho- for:tate there can be employed the other lower alkyl orthoformates, e.g. the methyl, propyl, and butyl orthoformates. In forming NPT 15392 the acetic anhydride forms the acetate of NPT 15392 and this is then hydrolized with alkali, e.g. sodium hydroxide. In place of an orthoformic acid ester formic acid can also be used. Example 2 UTILIZATION OF NPT 15459 TO PRODUCE NPT 15392. (Erythro-9-(2-hydroxy-3-nonyl)hypoxanthine 415 g of erythro-3-(2-hydroxy-3-nonyl)-4amino-imidazole-5-carboxamide (V) (1.55 moles) are suspended in 385 ml of orthoformic acid triethylester. 220 ml of acetic acid anhydride are added with stirring. The suspension that is obtained is heated with stirring up to 100-1050C. An exothermic reaction ensues with liberation of ethanol. The liberated ethanol is separated by distillation. The temperature of the reaction mixture is increased slowly up to 130-14OOC. Stirring is continued for about 3 hours, while the liberated ethanol is continuously separated by distillation. The reaction mixture is concentrated to a viscous syrup, which is stirred into a mixture of 415 ml of 306 aqueous WaOH and 1.68 liter of water. The brown solution is slightly acidified by addition of a solution of 123 ml of acetic acid in 1.5 liter of water. Erythro-9- (2-hydroxy-3-nonyl) -hypoxanthine (VI) crystallizes, is filtered by suction, washed with water and dried in vacuo at 600C. Yield: 350 g corresponding to 81.4% of theory Melting point (after repeated recrystallization from aqueous ethanol): 200-201OC Content by titration: 99.4% Content of threo isomer: 0.9% UTILIZATION OF NPT 15459 TO PRODUCE NOVEL DERIVATIVES OF NPT 15392 NPT 15459 and its homologues possess the ability to react with a variet of reagents which could lead to ring closure and the production of novel purine derivatives. By the judicious choice of reagents, it is possible to produce a number of 2-substituted derivatives of NPT 15392 and its homologues that could not be produced by other means. The scheme provided in the following diagram illustrates a number of such examples. EMI14.1 erythro-2-amino-g-(2-hydroxy-3-nouyl)-hypoxauthine In the reaction scheme just set forth R1 is the group EMI15.1 The 2,6-dichloro-purine compound in the above scheme can be converted to the 2-chloro hypoxanthine using conventional procedures, e.g. by refluxing with sodium hydroxide in the manner showy in Simon U.S. patent 4,221,909 Method D. The latter compound can then be converted to the corresponding 2-a.ino-hypoxanthine by reacting with methanolic an'monica in a manner analogous to that shown in Simon U.S, patent 4,221,909 Method B. Compounds of formula (3) where R is methyl can be made by reacting NPT 15459 or its homologues with ethyl orthcacetate rather than ethyl orthoformate. Corpourlds of formula (3) where R is ethyl can be made in similar manner by reacting NPT 15459 with ethyl orthopropionate. The immunomodulating activity of NPT 15459 was determined. The results are set forth below in Tables 1 and 2. In Table 1 the effect of NPT 15459 on con A Induced Proliferation is described. The procedure is described in Simon U.S. patent 4,221,909, column 24, line 12 to column 25, line 10. In Table 1 the effect of NPT 15459 on LPS Induced Proliferation is described In Table 2 the SRBC Induced Antibody Formation procedure employed was that shown in Simon EPO application 0036077 page 46. TABLE 1 IMMUNOMODULATING ACTIVITY NPT 15459 Mitogen Induced Lymphocyte Proliferation Concentration Test X Percent Change (Dosage) from Control cDm Control Con a induced 35,059 0 Proliferation .020 g/ml " " 35,747 +2 .500 " " " 30,920 -12 5.0 " " " 20.098 -43a 10.0 " " " 12,736 -66a Control LPS Induced 7044 0 Proliferation .02 g/ml " " 6184 -12 .5 " " " 6676 -6 5.0 " " " 4128 -42a 10.0 " " " 2449 -66a TABLE 2 IMMUNOMODULATING ACTIVITY NPT 15459 Antibody Formation Concentration Test X Percent Change (Dosage) from Control PFC/1D6 Cells Saline SR3C Induced 53 0 Antibody Formation .05 mg/kg .5 " 120 's2t .o " 66 157 -2' Formulations The compounds of the present invention can be fed to a mammal at a dosage of <RTI ID=17.7> 1-1000 mg/kg of body weight and could be anticipate to be active at levels as low as 0.0005 mg/kg. It is anticipated they may be administere in tablet or capsule form to humans and where solubility permits in the form of an aqueous syrur, or as solutions in oil, or where insoluble as a supension. Typical pharmaceutical formulations are described below: Capsule: NPT 15459 0.1-500 mg Avicel pH 101 (microcrystalline cellulose) to make 800 m. Suspension Aqueous suspensions can be made with a number of suspending agents incorporated with the active drug substances. Included as suspending agents are such substances as sodium carboxymethyl- cellulose, Na alginate gum, tragacanth, hvicel RC-591 (microcellulose), methylcellulose, Veegum, Xanthan gum. In addition to a suspending agent such substances as sweetners, flavors, colorants, preservatives, protective colloids, and dispersants may be added. Syrup Formulation NPT 15459 0.05 - 250 mg (or at maximum level of solubility) Corn Su-cr 3.25 µ. Distilled Water .05 g. FD and C Red 40 .00175 g. Sodium Saccarin .00250 g. Alcohol U.S.P. .08 g. Methyl paraben U.S.P. .005 g. Glycerin .001 g. Cherry flavor .31225 g. Fruit flavor .00825 9. Distilled water g.s.ad 5 ml. Tablet Formulation NPT 15459 0.1 - 500 mg Avicel pH 101 130 mg Starch, modified 20 ng Magnesium stearate U.S.P. 5.5 ng Polyvinylpyrrolidone 22 mg Stearic acid U.S.P. 30 mg

Claims: CLAIMS: 1. A compound having one of the formulae (1.) EMI20.1 where R is a lower alkyl, chlorine, or bromine and n is an integer from 1 to 5. 2. A compound according to claim 1 having formula (1). 3. A compound according to claim 1 having formula (2). 4. A compound according to claim 1 having formula (3). 5. A compound according to claim 4 where R is lower alkyl. 6. A compound according to claim 4 wherein R is chlorine or bromine. 7. A method of preparing a compound of claim 1 having formula (1) comprising reacting 2-amino-2-cyano-acetamine with an equimolar amount of a lower alkyl orthoformate to form a compound having the formula EMI21.1 where R2 is lower alkyl and reacting this compound with an equimolar amount of erythro EMI21.2 8. A process according to claim 7 carried out in the presence of acetonitrile as a solvent and pyridine as a catalyst. 9. A process of preparing a compound of the formula EMI22.1 comprising reacting a compound of formula (1) of claim 1 with an equimolar amount of a lower alkyl orthoformate in the presence of acetic anhydride. 10. A process according to claim 9 comprising removing the alcohol formed in the reaction and addinq alkali after removing the alcohol to neutralize the acetic anhydride. 11. A process of preparing a compound having the formula EMI22.2 comprising reacting a compound of formula (1) of claim 1 with an equimolar amount of cyanogen bromide. 12. A process of preparing a compound having the formula EMI23.1 comprising reacting a compound of formula (1) of claim 1 with (+) H2N=C-SCH3 X H2N where X is the anion of an acid. 13. A process of preparing a compound of the formula EMI23.2 comprising reacting a compound of formula (1) of claim 1 with an equimolar amount of phosgene. 14. A process according to claim 13 including the additional step of replacing the two ring attached oxygen atoms with chlorine or bromine comprising reaction 1 mole of the compound of formula (4) with 2 moles of POC13 or POBr3. 15. A composition comprising a compound according to any one of Claims 1 to 6 and a pharmaceutical carrier. 16. A composition according to Claim 15 in unit dosage form.. 17. A compound according to any one of Claims 1 to 6 for use as an immunomodulator or an immunopotentiator. 18. Use of a compound according to Claim I having formula (1) for preparing erythro-9-(2-hydroxy-3nonyl) hypoxanthine and its homologues, or for preparing a compound of formula (2) or (3).

Inventors: MUELLER, HANS-RUDOLF, SIMON, LIONEL NORTON, ZUTTER, HANS
Applicants: NEWPORT PHARMACEUTICALS INTERNATIONAL, INC.
Application year: 1983
Main classification: C07D233
IPC codes: C07D475, C07D473, C07D233, C07D241